

### AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** An isolated peptide of the formula: ~~X1X2X3~~ wherein wherein ~~X1 and X3 may be the same or different and each is an amino acid sequence comprising from 0 to 40 naturally or non-naturally occurring amino acid residues;~~

~~X2 is any amino acid sequence derived from or homologous to Hev b 5,~~

comprising a Hev b 5 T cell epitope said peptide comprising at least 5 contiguous amino acids of an amino acid sequence selected from the group consisting of:

- (i) amino acids 1-20;
- (ii) amino acids 37-56;
- (iii) amino acids 46-65;
- (iv) amino acids 55-74;
- (v) amino acids 82-101;
- (vi) amino acids 109-128; and
- (vii) amino acids 127-146

of Hev b 5 (SEQ ID NO:1) or homolog thereof,

~~and~~ wherein said peptide molecule is capable of interacting with T cells and modifying T cell function when incubated with cells from subjects having a condition characterised by an aberrant, unwanted or otherwise inappropriate immune response to Hev b 5 or a derivative, homolog, mutant, chemical equivalent or mimetic of said peptide.

2. **(Currently amended)** The peptide according to claim 1 wherein ~~X2 is an amino acid sequence of~~ said peptide is from 5 to 100-20 residues derived from, homologous to or contiguous with amino acids 1-151 inclusive or derivatives thereof of Hev b 5 in length.

3. **(Currently amended)** The peptide according to claim 2 wherein said amino acid sequence is ~~derived from, homologous to or contiguous with~~ amino acids 37-56 74 or 109-146 inclusive ~~or derivatives thereof~~ of Hev b 5 or homolog thereof.

4. **(Currently amended)** The peptide according to claim 2 wherein said amino acid sequence is ~~derived from, homologous to or contiguous with~~ amino acids 1-20, 19-110, and/or 109-146 46-65 inclusive ~~or derivatives thereof~~ of Hev b 5 or homolog thereof.

5. **(Currently amended)** The peptide according to claim 2 wherein said amino acid sequence is ~~derived from, homologous to or contiguous with~~ amino acids 37-56, 46-65, 55-74, 109-128 and/or 127-146 55-74 inclusive or derivatives thereof of Hev b 5 or homolog thereof.

6. **(Currently amended)** The peptide according to claim 5 2 wherein said amino acids are ~~46-65 and/or 109-128 inclusive or derivatives thereof~~ acid sequence is amino acids 109-128 inclusive of Hev b 5 or homolog thereof.

7. **(Currently amended)** The peptide according to claim 6 2 wherein said amino acids are ~~51-60 inclusive or derivatives thereof~~ acid sequence is amino acids 127-146 inclusive of Hev b5 or homolog thereof.

8. **(Currently amended)** The peptide according to claim 2 wherein said amino acid sequence comprises at least 5 amino acids derived from one or more of the following amino acid sequences:

MASVEVESAATALPKNETPE (SEQ ID NO: 2)

ASEQETADATPEKEEPTAAP <400>6 (SEQ ID NO: 6)

TPEKEEPTAAPAEPEAPAE <400>7 (SEQ ID NO: 7)

APAEPEAPAPETEKAAEEVEK <400>8 (SEQ ID NO: 8)

APEADQTTPEEKPAEPEPVA (SEQ ID NO: 11)

TKETETEAPAAPAEGEKPAE <400>14 (SEQ ID NO: 14)

AEEKPKITEAAETATTEVPV <400>16 (SEQ ID NO: 16).

9. **(Currently amended)** The peptide according to claim 8 wherein said amino acid sequence is derived from one or more of ~~<400>7~~ SEQ ID NO: 7 or ~~<400>14~~ SEQ ID NO: 14.

10. **(Currently amended)** The peptide according to claim 9 wherein said amino acid sequence is derived from ~~<400>7~~ SEQ ID NO: 7.

11. **(Currently amended)** The peptide according to claim 10 wherein said amino acid sequence ~~is derived from~~ comprises the following amino acid sequence:

EPTAAPAEPE <400>42 (SEQ ID NO: 42).

12.-22. **Canceled**


23. **(Withdrawn)** An antibody directed to Hev b 5 or derivative, homologue, analogue, chemical equivalent or mimetic thereof.

24. **(Withdrawn)** The antibody according to claim 23 wherein said antibody is a polyclonal antibody.

25. **(Withdrawn)** The antibody according to claim 23 wherein said antibody is a monoclonal antibody.

26. **(Withdrawn)** The antibody according to claim 25 wherein said antibody is 1C10, 6F6, 3G3 or 6A10.

27. **(Withdrawn)** An isolated peptide of the formula:



wherein:

$X_1$  and  $X_3$  may be the same or different and each is an amino acid sequence comprising from 0 to 40 non-naturally occurring amino acid residues;

$X_2$  is an amino acid sequence derived from or homologous to Hev b 5

and wherein said peptide molecule is capable of interacting with antibody from subjects having a condition characterised by aberrant, unwanted or otherwise inappropriate immune response to Hev b 5 or a derivative, homologue, analogue, mutant, chemical equivalent or mimetic of said peptide.

28. **(Withdrawn)** The peptide according to claim 27 wherein said antibody is 1C10, 6F6, 3G3 or 6A10.

29. **(Withdrawn)** An isolated peptide comprising an amino acid sequence derived from or homologous to Hev b 5 wherein said peptide is capable of interacting with antibody from subjects having a condition characterised by an aberrant, unwanted or otherwise inappropriate immune response to Hev b 5 or a derivative, homologue, analogue, mutant, chemical equivalent or mimetic of said peptide.

30. **(Withdrawn)** The peptide according to claim 29 wherein said antibody is 1C10, 6F6, 3G3 or 6A10.

31. **(Withdrawn)** An isolated nucleic acid sequence encoding or complementary to a sequence encoding the peptide according to any one of claim 1.

32. **(Currently Amended, Withdrawn)** A method for the treatment and/or prophylaxis of a condition in a subject, which condition is characterised by an aberrant, unwanted or otherwise inappropriate immune response to Hev b 5, said method comprising administering to said subject an effective amount of a peptide according to any one of claim 1 and/or an antibody according to claim 23 for a time and under conditions sufficient to remove or reduce the presence or function in said subject of T cells and/or antibodies directed to said Hev b 5.

33. **(Withdrawn)** The method according to claim 32 wherein said condition is latex hypersensitivity.

34. **Canceled**

35. **Canceled**

36. **(Currently Amended, Withdrawn)** A pharmaceutical composition comprising a peptide ~~and/or antibody~~ according to claims 1 ~~and~~ or an antibody according to claim 23 together with one or more pharmaceutically acceptable carriers and/or diluents.

37. **(Withdrawn)** A method of diagnosing or monitoring a condition in a mammal, which condition is characterised by an aberrant, unwanted or inappropriate response to Hev b 5, said method comprising screening for Hev b 5 reactive T cells and/or antibodies utilising the peptides according to claim 1.

38. **(Withdrawn)** The method according to claim 37 wherein said condition is latex hypersensitivity.

39. **(Withdrawn)** A method of qualitatively and/or quantitatively detecting Hev b 5, or peptides thereof, in a sample said method comprising screening for said Hev b 5 or peptides thereof utilising an antibody according to claim 23.

40. **(Currently amended)** A diagnostic kit ~~for use in the method of claim 37~~ comprising a peptide according to any one of claims 1 to 11, or 41-42.

41. **(New)** The peptide according to claim 2 wherein said amino acid sequence is amino acids 1-20 inclusive of Hev b 5.

42. **(New)** The peptide according to claim 2 wherein said amino acid sequence is amino acids 82-101 inclusive of Hev b 5.